Scopolamine model of delirium in rats and reversal of the performance impairment by aniracetam

Drug Development Research

Volumn 43, Issue 2, 1998, Pages 85-97

  Nakamura, Kazuo ^a   Kurasawa, Mitsue ^a   Tanaka, Yushiro ^a  

^a NIPPON ROCHE RESEARCH CENTER   (Japan)

Author keywords

Aniracetam; Choice reaction performance task; Delirium; Metabolites; Scopolamine

Indexed keywords

4 AMINOBUTYRIC ACID DERIVATIVE; ANIRACETAM; ANISIC ACID; DRUG METABOLITE; HALOPERIDOL; MUSCARINIC RECEPTOR; N ANISOYL 4 AMINOBUTYRIC ACID; PHYSOSTIGMINE; PIRENZEPINE; PYROGLUTAMIC ACID; RO 13 6680; SCOPOLAMINE; TACRINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BRAIN REGION; CHOLINERGIC SYSTEM; CONTROLLED STUDY; DELIRIUM; DRUG ACTIVITY; DRUG EFFECT; DRUG RECEPTOR BINDING; LOCOMOTION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; RESPONSE TIME; STATISTICAL ANALYSIS; TASK PERFORMANCE;

EID: 0031843091     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2299(199802)43:2<85::AID-DDR1>3.0.CO;2-L     Document Type: Article

References (66)

1. Alexander DA (1973): Attention dysfunction in senile dementia. Psychol Rep 32:229-230.
2. Baunez C, Nieoullon A, Amalric M (1995): Dopamine and complex sensorimotor integration: Further studies in a conditioned motor task in the rat. Neuroscience 65:375-384.
3. Broks P, Preston GC, Traub P, Poppleton C, Ward C, Stahl SM (1988): Modelling dementia: Effects of scopolamine on memory and attention. Neuropsychologia 26:685-700.
4. Bymaster FP, Heath I, Hendrix JC, Shannon HE (1993): Comparative behavioral and neurochemical activities of cholinergic antagonists in rats. J Pharmacol Exp Ther 267:16-24.
5. Carli M, Samanin R (1992): Serotonin2 receptor agonists and serotonergic anorectic drugs affect rats performance differently in a five-choice serial reaction time task. Psychopharmacology 106:228-234.
6. Cheal ML (1981): Scopolamine disrupts maintenance of attention rather than memory processes. Behav Neurol Biol 33:163-187.
7. Drachman DA, Noffsinger D, Sahakian BJ, Kurdziel S, Fleming P (1980): Aging, memory, and the cholinergic system: A study of dichotic listening. Neurobiol Aging 1:39-43.
8. + current. Eur J Pharmacol 141:153-157.
9. Dunnett SB (1985): Comparative effects of cholinergic drugs and lesions of nucleus basalis or fimbria-fornix on delayed matching in rats. Psychopharmacology 87:357-363.
10. Dunnett SB, Everitt BJ, Robbins TW (1991): The basal forebrain-cortical cholinergic system: Interpreting the functional consequences of excitotoxic lesions. TINS 14:494-501.
11. Egashira T, Takayama F, Yamanaka Y (1996): Effects of bifemelane on muscarinic receptors and choline acetyltransferase in the brains of aged rats following chronic cerebral hypoperfusion induced by permenent occlusion of bilateral carotid arteries. Jpn J Pharmacol 72:57-65.
12. Everitt BJ, Robbins TW, Gaskin M, Fray PJ (1983): The effects of lesions to ascending noradrenergic neurons on discrimination learning and performance in the rat. Neuroscience 10:397-410.
13. 3H]Aniracetam binds to specific recognition sites in brain membranes. J Neurochem 65:912-918.
14. Flynn DD, Mash DC (1989): Multiple in vitro interactions with and differential in vivo regulation of muscarinic receptor subtypes by THA. J Pharmacol Exp Ther 250:573-581.
15. Giovannini MG, Rodino P, Mutolo D, Pepeu G (1993): Oxiracetam and aniracetam increase acetylcholine release from the rat hippocampus in vivo. Drug Dev Res 28:503-509.
16. 3H]DOPA in various regions of the brain. J Neurosci 13:655-669.
17. Hikosaka O (1995): Can we observe attention? Seitai No Kagaku 46:67-71.
18. Himori N, Mishima K (1994): Amelioration by aniracetam of abnormalities as revealed in choice reaction performance and shuttle behavior. Pharmacol Biochem Behav 47:214-225.
19. Himori N, Watanabe H, Matsuura A, Umeda Y, Kuwahara T, Takemoto C, Takamiya M, Yajima T, Tanaka Y, Nakamura K (1986): General pharmacological properties of aniracetam, a cerebral insufficiency improver. Jpn Pharmacol Ther 14(Suppl 4):93-128.
20. Jones DNC, Barnes JC, Kirkby DL, Higgins GA (1995): Age-associated impairments in a test of attention: Evidence for involvement of cholinergic systems. J Neurosci 15:7282-7292.
21. Jones GMM, Sahakian BJ, Levy R, Warburton DM, Gray JA (1992): Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer's disease. Psychopharmacology 108:485-494.
22. Kaul P (1962): Enzyme inhibiting action of tetrahydroaminoacridine and its structural fragments. J Pharm Pharmacol 14:243-248.
23. Kessler J, Markowitsch HJ, Sigg G (1986): Memory related role of the posterior cholinergic system. Int J Neurosci 30:101-119.
24. Kojima T, Atsumi Y, Ichise K, Uchiyama M, Shimazono Y (1983): A polysomnographic study of the delirious state caused by administration of biperiden. Psychiatry (Japan) 25:197-206.
25. Kubota A, Kurasawa M, Furuya I (1986): Pharmacological study on aniracetam. I. Choice reaction time-shortening action of aniracetam in aged rats (1) - Effective doses and reference drugs. Jpn Pharmacol Ther 14(Suppl 4):47-54.
26. Levey AI, Kitt CA, Simonds WF, Price DL, Brann MR (1991): Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. J Neurosci 11:3218-3226.
27. Martin JR, Haefely WE (1993): Pharmacology of aniracetam. A novel pyrrolidinone derivative with cognition enhancing activity. Drug Invest 5(Suppl 1):4-49.
28. Mayersohn M, Roncari G, Wendt G (1993): Disposition pharmacokinetics and metabolism of aniracetajn in animals. Drug Invest 5 (Suppl 1):73-95.
29. Mesulam M-M, Mufson EJ, Wainer BH, Levey AI (1983): Central cholinergic pathways in the rat: An overview based on an alternative nomenclature (Ch1-Ch6). Neuroscience 10:1185-1201.
30. Milar KS (1981): Cholinergic drug effects on visual discriminations: A single detection analysis. Psychopharmacology 74:383-388.
31. Muir JL, Dunnett SB, RobbinsTW, Everitt BJ (1992): Attentional functions of the forebrain cholinergic systems: Effects of intraventricular hemicholinium, physostigmine, basal forebrain lesions and intracortical grafts on a multiple-choice serial reaction time task. Exp Brain Res 89:611-622.
32. Muir JL, Everitt BJ, Bobbins TW (1994): AMPA-induced excitotoxic lesions of the basal forebrain: A significant role for the cortical cholinergic systems in attentional function. J Neurosci 14:2313-2326.
33. Muir JL, Everitt, Robbins TW (1995): Reversal of visual attentional function following lesions of the cholinergic basal forebrain by physostigmine and nicotine but not by the 5-HT3 receptor antagonist, ondansetron. Psychopharmacology 118:82-92.
34. Nakajima T, Takahashi M, Okada T (1986): Pharmacological study of aniracetam. VI. Effects of aniracetam on muscarinic acetylcholine receptors in the rat hippocampus. Jpn Pharmacol Ther 14(Suppl 4):85-91.
35. Ober BA, Koss E, Friedland RP, Delis DC (1985). Processes of verbal memory failure in Alzheimer-type dementia. Brain Cognit 4:90-103.
36. O'Connor KP (1980): Slow potential correlates of attention dysfunction in senile dementia. Biol Psychol 11:193-202.
37. Otomo E, Hirai S, Hasegawa K, Araki G, Nishimura T, Inanaga K(1987): Usefulness of aniracetam for cerebrovascular disorders: Double-blind trial against Ca hopantenate. J Clin Exp Med (Igaku No Ayumi) 140:989-1016.
38. Otomo E, Hirai S, Terashi A, Hasegawa K, Tazaki Y, Araki G, Itoh E, Nishimura T, Furukawa T (1991): Clinical usefulness of aniracetam for psychiatric symptoms in patients with cerebrovascular disorders: Double-blind trial against placebo. Igaku No Ayumi 156:143-187.
39. Parrott AC (1986): The effects of transdermal scopolamine and four dose levels of oral scopolamine (0.15,0.3,0.6 and 1.2 mg) upon psychological performance. Psychopharmacology 89:347-354.
40. 2 muscarine receptors. Neurosci Lett 88:281-285.
41. Perry EK, Smith CJ, Court JA, Bonham JR, Rodway M, Atack JR (1988): Interaction of 9-amino-1,2,3,4-THA (THA) with human cortical nicotinic and muscarinic receptor binding in vitro. Neurosci Lett 91:211-216.
42. Pietrusiak N, Vincent GP, Harney R, Sepinwall J (1986): Use of proximal vs. distal cues in a water maze task is strain dependent: Aniracetam (Ro 13-5057) reverses distal cue deficits. Soc Neurosci Abstr 12:705.
43. Posner MI (1994): Attention: The mechanisms of consciousness. Proc Nad Acad Sci USA 91:7398-7403.
44. Ridley RM, Barratt NG, Baker HF (1984): Cholinergic learning deficits in the marmoset produced by scopolamine and ICV hemicholinium. Psychopharmacology 83:340-345.
45. Robbins TW, Everitt BJ, Marston HM, Wilkinson J, Jones GH, Page KJ (1989): Comparative effects of ibotenic acid- and quisqualic acid-induced lesions of the substantia innominata on attentional function in the rat: Further implications for the role of the cholinergic neurons of the nucleus basalis in cognitive processes. Behav Brain Res 35:221-240.
46. Sahakian BJ (1988): Cholinergic drugs and human performance. In Iversen LL, Iversen SD, Snyder SH (ed): Handbook of Psychopharmacology, Vol. 20. New York: Plenum Press, pp 393-424.
47. Sahakian BJ, Owen AM, Morant NJ, Eagger SA, Boddington S, Crayton L, Crockford HA, Crooks M, Hill K, Levy R (1993): Further analysis of the cognitive effects of tetrahydroaminoacridine (THA) in Alzheimer s disease: Assessment of attentional and mnemonic function using CANTAB. Psychopharmacology 110:395-401.
48. Saletu B, Grünberger J (1983): Cerebral hypoxic hypoxidosis: Neurophysiological, psychometric and pharmacotherapeutic aspects. Adv Biol Psychiat 13:146-164.
49. Saletu B, Grünberger J, Linzmayer L (1980): Quantitative EEG and psychometric analyses in assessing CNS-activity of Ro13-5057 - a cerebral insufficiency improver. Meth Find Expt Clin Pharmacol 2:269-285.
50. Santucci V, Fournier M, Worms P, Keane P, Bizière K (1989): Cerebral-activating (EEG) properties of two inverse agonists and of an antagonist at the benzodiazepine receptor in the rat. Naunyn Schmiedetergs Arch Pharmacol 340:93-100.
51. Sarter M (1994): Neuronal mechanisms of attentionl dysfunction in senile dementia and schizophrenia: Two sides of the same coin? Psychopharmacology 114:539-550.
52. Schwam E, Keim K, Cumin R, Gamzu E, Sepinwall J (1985): The effects of aniracetam on primate behavior and EEG. Ann NY Acad Sci 444:482-184.
53. Senin U, Parnetti L, Cucinotta D, Criscuolo D, Longo A, Marini G, (1993): Clinical experience with aniracetam in the treatment of senile dementia of the Alzheimer's type and related disorders. Drug Invest 5(Suppl 1):96-105.
54. Shannon HE, Bymaster FP, Hendrix JC, Quimby SJ, Mitch CH (1995): Novel alkoxy-oxazolyl-tetrahydropyridine muscarinic cholinergic receptor antagonists. Psychopharmacology 117:208-215.
55. Spignoli G, Pepeu G (1987): Interactions between oxiracetam, aniracetam and scopolamine on behavior and brain acetylcholine. Pharmacol Biochem Behav 27491-495.
56. Sleckler T, Inglis W, Winn P, Sahgal A (1994): The pedunculopontine tegmental nucleus: A role in cognitive processes? Brain Res Rev 19:298-318.
57. Steriade M, Llinas RR (1988): The functional states of the thalamus and the associated neuronal interplay. Physiol Rev 68:649-742.
58. Steriade M, Datta S, Pare D, Oakson G, Dossi RC (1990): Neuronal activities in brainstem cholinergic nuclei related to tonic activation processes in thalamocortical systems. J Neurosci 10: 2541-2559.
59. Warburton DM, Brown K (1971): Attenuation of stimulus sensitivity induced by scopolamine. Nature 230:126-127.
60. Warburton DM, Brown K (1972): The facilitation of discrimination performance by physostigmine sulphate. Psychopharmacologia 27:275-284.
61. 3H]quinuclidinyl benzilate binding to rat cerebral cortical and cardiac muscarinic cholinergic sites. I. Characterization and regulation of agonist binding to putative muscarinic subtypes. J Pharmacol Exp Ther 117:208-215.
62. Wesnes K, Simpson PM (1988): Can scopolamine produce a model of the memory deficits seen in memory and aging? In Gruneberg MM, Morris PE, Sykes RN (ed): Practical Aspects of Memory: Current Research and Issues: Vol. 2. Clinical and Educational Implications. Chichester UK: John Wiley & Sons, pp 236-242.
63. Wesnes K, Warburton DM (1983). Effects of scopolamine on stimulus sensitivity and response bias in a visual vigilance task. Neuropsychobiology 9:154-157.
64. Wesnes K, Warburton DM (1984): Effects of scopolamine and nicotine on human rapid information processing performance. Psychopharmacology 82:147-150.
65. Wesnes K, Warburton DM, Matz B (1983): Effects of nicotine on stimulus sensitivity and response bias in a visual vigilance task. Neuropsychobiology 9:41-44.
66. Wesnes K, Anand R, Simpson P, Christmas L (1990): The use of a scopolamine model to study the potential nootropic effects of aniracetam and piracetam in healthy volunteers. J Psychopharmacol 4:219-232.